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ABSTRACT 17 
Introduction: Cooling of the body is used to treat hyperthermic individuals with heatstroke or to 18 
depress core temperature below normal for neuroprotection. A novel chemically activated, 19 
unpowered cooling device, CAERvest®, was investigated for safety and efficacy, with the 20 
feedback used to inform device development.  21 
Methods: Eight healthy male participants (body mass 79.9±1.9kg and body fat percentage 22 
16.1±3.8%) visited the laboratory (20°C, 40% RH) on four occasions. Following 30min rest, 23 
physiological and perceptual measures were recorded. Participants were then fitted with the 24 
CAERvest® proof of concept (PoC), prototype 1 (P1), 2 (P2) or 3 (P3) for 60min. Temperature, 25 
cardiovascular and perceptual measures were recorded every 5min. After cooling, the 26 
CAERvest® was removed and the torso was checked for cold–related injuries.  27 
Results: Temperature measures significantly (p<0.05) reduced pre–to–post in all trials. Larger 28 
reductions in core and skin temperature were observed for PoC (–0.36±0.18 and –1.55±0.97°C) 29 
and P3 (–0.36±0.22 and –2.47±0.82°C), compared to P1 and P2. No signs of cold–related injury 30 
were observed at any stage.  31 
Conclusion: This study demonstrates the CAERvest® is an effective device for reducing body 32 
temperature in healthy normothermic individuals without presence of cold injury. Further 33 
research in healthy and clinical populations within controlled and field–settings is warranted. 34 
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BMI body mass index 43 
BSA body surface area 44 
CBT core body temperature 45 
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Tchest calf temperature 63 
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TSS thermal sensation  66 
Tskin skin temperature 67 
TTM targeted temperature management 68 
Uosm urine osmolality 69 
Usg urine specific gravity 70 
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1.0 INTRODUCTION 73 
Active cooling treatment is used to reduce an abnormally or dangerously elevated core body 74 
temperature (CBT), as in heat related illnesses (HRI). It may also be used to reduce a patient’s 75 
CBT below normal (e.g. targeted temperature management [TTM]) during cardiac surgery and 76 
as neuroprotective treatment to reduce brain damage following a loss of blood supply, as in cases 77 
of sudden cardiac arrest with return of spontaneous circulation (ROSC) (1–4). 78 
HRI present on a continuum of pathological states that range from mild to severe (5). If 79 
undetected or ineffectively treated, mild HRI can lead to heatstroke, a severe, life–threatening 80 
illness (6). Exertional heatstroke (EHS), a consequence of attenuated whole–body heat loss and 81 
the inability to dissipate metabolic heat production, can occur while physically active in either 82 
temperate or, hot humid conditions (7). Predisposing risk factors include lack of acclimatisation, 83 
dehydration, sleep deprivation, low aerobic fitness and diverse biophysical characteristics (6), 84 
meaning the onset can be sporadic and unpredictable.  85 
CBT cooling is employed within sporting and occupational health settings prior to and between 86 
aerobic exercise or firefighting tasks, which have shown to improve performance in heat stress 87 
and reduce physiological and, or perceptual strain (8–10). Methods employed to actively cool 88 
vary according to setting and application, while HRI treatment is largely dependent upon the 89 
duration and extent to which CBT exceeds critical levels (7). Examples of these modalities 90 
include whole–body cold water immersion (CWI) (11), ice slurry ingestion (12), pre–prepared 91 
ice packs, evaporative techniques or a combination thereof (13). In contrast, early cooling for 92 
post–ROSC patients is difficult pre–admission to hospital due to equipment portability and 93 
effectiveness (14), while the precise CBT to be targeted for TTM remains controversial (3).  94 
Currently, available cooling techniques are either external, non–invasive treatments which 95 
provide surface heat exchange, or internal, invasive devices that reduce blood temperature 96 
through infused cold saline or nasal spray (15,16). Difficulties thus far have been the design of a 97 
device that achieves sufficient and extended cooling non–invasively in the field, pre–admission 98 
to the hospital and without use of cooling tanks, refrigeration units, or electrical supply. The 99 
CAERvest®, a chemically powered, easy to activate, endothermic device that covers the torso, 100 
upper abdomen and extends onto the neck, purports to overcome these problems. 101 
We undertook an initial controlled pilot study in healthy normothermic individuals to establish 102 
whether CAERvest® prototypes could significantly reduce core and skin temperature effectively 103 
over a 60 min period of cooling. Various prototypes were simultaneously assayed to compare 104 
efficacy and establish product safety. This testing was also intended to provide data to satisfy 105 
regulatory requirements. It was hypothesised there would be no significant difference in core 106 
 
 
temperature in a defined group of participants within– and between–data collected over the 107 
cooling period in any prototype.   108 
 
 
2.0 MATERIALS AND METHODS: 109 
2.1 Participants 110 
Eight moderately active, male participants (mean (M) ± standard deviation [SD]; age 27±5 years, 111 
stature 179±4 cm, nude body mass [NBM] 79.9±1.9 kg, body surface area [BSA] 1.99±0.05 m2, 112 
body mass index [BMI] 24.4±0.2 and body fat percentage 16.1±3.8 %) volunteered for the study 113 
having provided written informed consent. Male participants were recruited to control for 114 
thermoregulation deviation around the menstrual cycle (17). Participants confirmed they were 115 
healthy, taking no medication and had no serious medical history or prior cold–related injuries. 116 
The study was approved by the Institution’s Research Ethics and Governance Committee and 117 
conducted in accordance with the Declaration of Helsinki of 1975, as revised in 2013. Participants 118 
refrained from caffeine, alcohol consumption and prolonged strenuous activity for 24 h prior to 119 
testing. Participants also abstained from food for 2 h before testing and to arrive in a euhydrated 120 
state (18).  121 
2.2 Experimental design 122 
Each participant visited the laboratory on four occasions, separated by >72 h to complete the first 123 
three CAERvest® trials (proof of concept [PoC], prototype 1 [P1] and prototype 2 [P2]), which 124 
were counterbalanced using a cross–over design. This then informed the product development 125 
for the final CAERvest® trial (prototype 3 [P3]), which was completed 21 days after their first 126 
visit by all of the participants (Figure 1). Trials were completed in temperate conditions (20°C, 127 
40% relative humidity), with participants wearing only shorts and t–shirt at similar times of the 128 
day to minimise circadian rhythm variations (19). Each visit followed the same protocol (Figure 129 
2), although the allocated CAERvest® prototype changed per trial.  130 
2.3 Physiological measures and equipment 131 
Body fat was estimated using skinfold calipers (Harpenden, UK,) across four standard sites (20). 132 
Participants provided, in privacy, a fresh mid–flow urine sample which was assessed for 133 
osmolality (Uosm) (Osmocheck, Vitech Scientific, Japan) and specific gravity (Usg) (hand 134 
refractometer, Atago, Japan) to indicate hydration status. Stature and NBM were measured using 135 
physician (Detecto scale company Inc., USA) and weighing scales (Adam GFK 150, Equipment 136 
Co., UK) respectively, for BMI and BSA calculation (21). Blood pressure (BP) was assessed 137 
using an automatic monitor (Boso Medicus PC, Cranlea & Company, UK). Rectal temperature 138 
(Tre) was assessed continuously using a rectal probe (4600 thermometer, Henleys medical 139 
supplies, UK) inserted 10 cm past the anal sphincter. Although minor delays to rapid transients 140 
are associated with Tre when compared with esophageal measurement, the equipment’s accuracy 141 
is ±0.13°C (22). Heart rate (HR) (Polar Electro, Finland) monitors were affixed and skin surface 142 
 
 
telemetry thermistors (U–type connected to Gen II GD38 transmitter, Eltek, UK) were attached 143 
to four sites (mid–belly of the pectoralis major, biceps brachii, rectus femoris and gastrocnemius). 144 
Data was transmitted wirelessly from a logging device (RX250AL 1000 series wireless squirrel 145 
logger, Eltek, UK), which is accurate to <0.1°C (23). M weighted skin temperature (Tskin) were 146 
estimated using the equation of Ramanthan, (24); M Tskin = 0·3 × (Tchest+Tarm)+0·2 × (Tthigh+Tcalf). 147 
Where Tchest, Tarm, Tthigh and Tcalf are chest, arm, thigh and calf temperature, respectively.  148 
2.4 Perceptual measures 149 
Participants were familiarised to the perceptual scales on their first visit. These included thermal 150 
sensation (TSS) on an 8–point scale (0 = unbearably cold – 8 = unbearably hot) (25); feeling on 151 
a 10–point scale (+5 = very good – –5 = very bad) (26); cold discomfort on a 10–point scale (0 = 152 
comfortable with no experience of cold – 10 = unbearably cold) (27) and shivering on a 4–point 153 
scale (0 = absence – 3 = severe) (28). 154 
2.5 CAERvest® devices and development 155 
The CAERvest® devices contain a precise quantity of non–toxic chemical blend (developed by 156 
BodyChillz, UK) which, when combined with a defined volume of water from an external 157 
reservoir, undergoes an endothermic dissolution process and cools for >1 h. Reservoirs were 158 
placed in a water–bath (Fischer Scientific DMU19, UK) to control water temperature (18±1°C), 159 
as this represented a reasonable storage temperature for a commercial device. The PoC device 160 
comprised three separate compartmentalised, dual layer, polyethylene modules filled with blend 161 
and activated by 0.8 L of water. One was placed underneath the participant’s back, two were 162 
placed across the torso and another smaller module was placed around the neck. A total 4.05 kg 163 
of chemical was applied.  164 
The subsequent prototypes (P1, P2 and P3) were larger, single module designs intended to target 165 
high blood flow regions in neck, axillae and groins and allow for cardiopulmonary resuscitation 166 
(CPR), defibrillation or post resuscitation care. The CAERvest® are also compatible with the 167 
LUCASTM and Autopulse® chest compression systems. The P1 was the first single module design 168 
which covered the torso and groins of the participant and the filling mechanism was as per the 169 
PoC. A cellulose matrix was introduced in the P2 along with an incorporated neck section to cool 170 
the neck vessels preferentially. A solid non–spill quick disconnect coupling was employed to fill 171 
this prototype, with the female attached to the module and male to the reservoir. It was concluded 172 
after testing the PoC, P1 and P2 prototypes that the polyethylene material was too rigid and 173 
insufficiently elastic in nature. Therefore, a further prototype (P3) as displayed in Figure 3, 174 
retained the quick–disconnect coupling for filling and used 150 mm micron polyurethane on the 175 
inner surface. Nylon coated polyurethane was adopted on the outer portions of the device to 176 
improve insulation for the non–contact surface. The P3 design also removed the sections 177 
 
 
specifically targeting the neck and groin, which were found to be difficult to position, and 178 
increased coverage over the shoulders. The internal channels were redesigned such that fluid 179 
entering through the inlet port would push any entrapped air towards newly–introduced one–way 180 
valves at the apex of the neck. These valves allowed entrapped air to pass out without causing 181 
airlock, fluid loss or points of insulation. The expanding cellulose matrix then caused the device 182 
to swell upon fluid introduction and take on a garment–like configuration which improved patient 183 
comfort, ensured homogeneity of cooling, minimised movement of the incorporated chemicals 184 
in transit and reduced the incidence of cold spots. 185 
2.6 Safety 186 
Signs and symptoms of cold–related injuries were assessed on removal of the CAERvest® device 187 
and after the re–warming period. Skin surface was assessed for blistering, oedema and severe 188 
erythema, with trial termination if present (zero incidences). Reappraisal of signs and symptoms 189 
of cold injury was completed by telephone contact 24 h later. 190 
2.7 Experimental procedures 191 
Hydration status and anthropometric measures were completed on each participant prior to each 192 
trial. Temperature and cardiovascular measuring equipment was then attached before a 30 min 193 
baseline rest in a supine position. At the end of this, the allocated CAERvest® prototype was 194 
applied for 60 min. It was removed early at the participant’s request (one incidence at 50 min 195 
during the PoC trial), or if Tre dropped 1.5°C below resting levels (zero incidences). Cold injury 196 
assessments were then completed prior to a re–warming period, where CBT returned naturally, 197 
or was aided using extra clothing and light exercise at the participant’s discretion. Temperature, 198 
cardiovascular and perceptual measures were continuously monitored throughout and recorded 199 
at 5 min intervals. 200 
2.8 Safety follow up 201 
Twenty four hours after each trial, follow–up questionnaires and telephone conversations were 202 
conducted to account for any adverse effects of cooling (one minor headache).  203 
2.9 Statistical analyses 204 
The trials were an open study of efficacy, assessed by temperature changes over time while using 205 
the four CAERvest® prototypes. All data are presented as M ± SD and were assessed for normality 206 
and sphericity prior to statistical analysis. Two way, repeated measure Analysis of Variance 207 
(ANOVA) were used to test for differences in temperature, cardiovascular and perceptual 208 
responses between and within each trial at 5 min intervals. One way repeated measures ANOVA 209 
were used to test for the differences in the lowest point and change (∆) in temperature and 210 
 
 
cardiovascular measures within– and between–trials. Where appropriate, Bonferroni adjusted 211 
pairwise comparisons were used to identify where differences occurred. Lowest M values and ∆ 212 
in perceptual scales (non–parametric data) were analysed using a Friedman test, with post–hoc 213 
analysis using a Wilcoxon signed–rank test. Data were analysed using SPSS version 20.0, with 214 
significance set at p≤0.05. Effect size for main effects and interactions are presented as partial 215 
eta squared (ηp2), while meaningful differences between related samples during the trials were 216 
evaluated using Cohen’s d (29). Effect size were categorised as small (0.2), moderate (0.5) and 217 
large (0.8). Typical error of measurement (TEM) was calculated from the SD of the M difference 218 
during 30 min baseline in Tre and Tskin between the trials, multiplied by 1 squared, then divided 219 
by √2 (30) and expressed as a M coefficient variation (CV %). Statistical analysis on resting data 220 
within the sample population used within this study presented predefined limits in TEM (CV) of 221 
0.20°C (0.5%) for Tre and 0.64°C (2.2%) for Tskin. TEM were used to demonstrate clinically 222 
relevant trends within changes in Tre and Tskin when investigating the CAERvest® devices. 223 
  224 
 
 
3.0 RESULTS: 225 
3.1 Physical characteristics 226 
Participants arrived in similar physiological states across trials with no differences in preliminary 227 
measures (all p>0.05) (Table 1), apart from M systolic BP, which was elevated (F(3,21)=3.23, 228 
p=0.04, ηp2=0.3) prior to the PoC trial. 229 
3.2 Baseline measures 230 
No within– or between–participant differences were observed in Tre (F(3,21)=0.48, p=0.70, 231 
ηp2=0.1) or Tskin (F(3,21)=0.03, p=0.99, ηp2=0.0) across trials. Nor were differences found in HR 232 
(F(3,21)=0.47, p=0.71, ηp2=0.1) or perceptual measures of TSS (F(3,21)=0.30, p=0.82, ηp2=0.0), 233 
shivering (F(3,21)=1.00, p=0.41, ηp2=0.1), feeling (F(3,21)=1.00, p=0.42, ηp2=0.1), or cold 234 
discomfort (F(3,21)=0.78, p=0.56, ηp2=0.1) scales (Table 2). 235 
3.3 Cooling measures 236 
Temperature, cardiovascular and perceptual measures within– and between–CAERvest® 237 
trials: 238 
A main effect for Tre (F(6,42)=5.35, p=0.004, ηp2=0.4) and Tskin (F(6,36)=3.46, p=0.01, ηp2=0.4) 239 
occurred in all four trials, with significant pre–to–post reductions (Figure 4 and Table 3). On one 240 
occasion the PoC was removed at 50 min upon the participant’s request. ∆Tre was significantly 241 
greater (p=0.047) during the PoC trial (–0.36±0.18°C, d=1) compared to the P1 (–0.17±0.13°C, 242 
d=0.9). Moreover, during the P3 trial the ∆Tskin (–2.47±0.82°C, p=0.001, d=1) were significantly 243 
greater than the P2 trial (–0.98±0.93°C, d=0·7) (Table 3).  244 
There was a significantly larger ∆Tre (F(7,49)=5.33, p=0.00, ηp2=0.4) during the CAERvest® 245 
cooling period compared to the ∆Tre during baseline rest. This was found within the PoC (p=0.01) 246 
and P3 (p=0.01) trials, but not the P1 (p=0.45) or P2 (p=0.28) trials. A similar interaction effect 247 
was found for ∆Tskin (F(7,49)=37.24, p=0.00, ηp2=0.8) within the PoC (p=0.02), P1 (p=0.01) and 248 
P3 (p=0.00) trials, but not for P2 (p=0.09). 249 
An interaction effect occurred between time and CAERvest® in shivering (F(36,108)=1.55, 250 
p=0.04, ηp2=0.3) and cold discomfort (F(36,108)=2.345, p=0.001, ηp2=0.4) scales. Shivering 251 
(Z=–2.04, p=0.04) and cold discomfort (Z=–2.23, p=0.03) scales were significantly greater during 252 
the PoC (1±1 and 5±2, respectively) compared to the P1 trial (0±0 and 4±2, respectively). Cold 253 
discomfort (Z=–2.13, p=0.03) scales were also higher during the P3 (5±3) compared to P2 trial 254 
(3±2) (Table 4). 255 
 
 
An interaction effect between time and CAERvest® occurred in Tre (F(36,216)=1.91, p=0.003, 256 
ηp2=0.2) and Tskin (F(36,72)=2.60, p=0.001, ηp2=0.6), as displayed within Figure 4 and 5. 257 
No interactions were present in HR (F(36,144)=0.36, p=1.00, ηp2=0.1), TSS (F(36,108)=1.497, 258 
p=0.06, ηp2=0.3), or feeling (F(36,108)=1.24, p=0.20, ηp2=0.3) scales in the same period. 259 
3.4 Device safety analysis 260 
There was no evidence of cold–related injuries across all four CAERvest® prototypes. The only 261 
symptoms resulting from the trials were mild skin paleness on removal of the device and one 262 
reported headache within 6 h of PoC removal. Neither of these symptoms were considered to 263 
represent a serious adverse event. Headaches have been recorded in other cooling garment studies 264 
(31).  265 
  266 
 
 
4.0 DISCUSSION 267 
The aim of this study was to inform the development and investigate the safety and efficacy of a 268 
series of CAERvest® prototypes. Therefore, the study was designed to examine the null 269 
hypothesis, that there would be no significant difference in CBT in a defined group of participants 270 
during the cooling period in any prototype. We found significant reductions in Tre and Tskin with 271 
each device. The PoC and P3 CAERvest® were found to provide greater temperature reductions 272 
than the P1 and P2, suggesting improved design. It is postulated that in the PoC this may be 273 
because of increased mass and in the P3, despite reduced chemical mass, improved surface area 274 
coverage and thermal coupling to the skin. We found no evidence of important cold–related signs 275 
or symptoms from the CAERvest® devices during the cooling period, or in the subsequent 24 h. 276 
As the CAERvest® was being developed during the study, no comparisons were made with other 277 
similar devices, although future studies will address this. 278 
4.1 Comparisons to other cooling modalities 279 
Previous studies investigating surface cooling devices have reported effective (32–39) and 280 
ineffective (40–46) physiological responses in athletic performance, and thermoregulatory strain 281 
reductions within hyperthermic individuals. As EHS treatment requires a rapid cooling rate of 282 
0.1–0.2°C·min–1 (47), Lopez et al. (44), DeMartini et al. (45) and Flouris et al. (11) suggest the 283 
continued use of CWI as the standard for hyperthermic individuals, with reported cooling rates 284 
of 0.1–0.35°C·min–1. This is opposed to the less effective treatment of ice–wet towels 285 
(0.11°C·min–1), ice packs (0.03°C·min–1) and fans (0.02°C·min–1) (48). Within this study the 60 286 
min cooling rate for PoC and P3 were 0.01°C·min–1, while they were 0.003°C·min–1 for the P1 287 
and P2, however, the authors acknowledge the normothermic population tested and associated 288 
study limitations which are later discussed, although there still remains distinct advantages of a 289 
portable, on–site method. 290 
Further, other pre– and in–hospital surface cooling systems which have been used upon 291 
hyperthermic or cardiac arrest casualties, include the CritiCool (Curewrap™, MTRE, Yavne, 292 
Israel), Blanketrol III (Kool–Kit®, Cincinnati Sub–Zero, OH, USA), EMCOOLS (Flex.Pad®) 293 
and Artic Sun® (Medivance, Louisville, CO, USA) have reported cooling rates of 1.5–3.5°C·h–294 
1 (49,50). While InnerCool STX (Phillips, Best, Netherlands) and Thermogard XP® (ZOLL) 295 
intravascular systems report 2–5°C·h–1 (49). Finally, the intranasal device, RhinoChill® 296 
(BeneChill, CA, USA) reports 1.75°C reductions in the first hour of cooling (16,51). However, 297 
the large variation in cooling suggests product design and function play a key role in achieving 298 
clinically important reductions. Although, it is recognised that disparity may also result from 299 
alternate methodologies, cooling modalities, aerobic activity and the use of hyperthermic or 300 
cardiac arrest patients. These differences make it very difficult to compare across studies. There 301 
 
 
are however, disadvantages associated with these pre–hospital methods, including trivial benefits 302 
of evaporative fanning or misting (52), unconscious individuals are unable to ingest ice slurries, 303 
powered refrigerator requirements and impracticality of CWI, thus failing to provide a portable 304 
or flexible solution. Moreover, infusing cold saline intravenously is invasive, requires specialist 305 
training and causes additional stress to the circulatory system, often with deleterious effects 306 
(53,54). The in–hospital surface cooling devices are effective, but require electrical supply, 307 
refrigeration and are sometimes restricted to intensive care units. Finally, the intranasal device, 308 
can only be used on unconscious individuals and has large consumable costs (55). 309 
4.2 Physiological responses  310 
Tre was shown to reduce significantly pre–to–post while using all four CAERvest® designs, with 311 
the largest reported reductions observed in the PoC (–0.36±0.18°C) and P3 (–0.36±0.22°C) trials. 312 
Although the PoC implemented a larger surface area of cooling (56), there were no differences 313 
compared with the P3 CAERvest®. It is suggested the large range in Tre reductions during the 314 
PoC (–0.12 – –0.64°C), P1 (–0.12 – –0.41°C), P2 (–0.07 – –0.41°C) and P3 (–0.07 – –0.65°C) 315 
trials highlight inter–individual variances within the sample population. Significantly greater ∆Tre 316 
and ∆Tskin were observed during the cooling period compared to the bassline resting period during 317 
the PoC and P3 trials, as opposed to no difference during the P1 and P2. Thus, highlighting the 318 
greater effect of CBT cooling compared to a no–cooling control state.  319 
The observed Tskin reductions (2–3°C) are in line with previously cooled hyperthermic (44) and 320 
normothermic (37) individuals in warm conditions. Tskin during the P3 trial was significantly 321 
lower in the latter stages of the cooling period compared to the PoC and P2 trial, suggesting 322 
effective and prolonged cooling. Reportedly, optimal vasodilation, core to skin thermal gradient 323 
and therefore, a greater heat flux occurs at Tskin ~33–35°C (32). Tskin in this study reduced to 324 
<33°C in all four trials. Although, this may have appeared as chest and tricep skin thermistors 325 
were placed underneath the CAERvest® devices, leading to larger magnitudes of M Tskin declines, 326 
as similarly observed by Teunissen et al. (57).  327 
While the authors acknowledge the temperature reductions within the study are comparatively 328 
modest, it is suggested the limited reductions were observed because the study was performed in 329 
a young, asymptomatic healthy population of moderate fitness levels. These individuals may 330 
present characteristics similar to those heat–acclimatised, such as lower internal temperature set 331 
points (58) and modified thermoregulatory mechanisms, with improved capacity for 332 
vasoconstriction (59). Therefore, participants may have been particularly resilient to an external 333 
cold induced stimulus and, subsequently, more effective in defending their CBT through 334 
homeostasis. Those with predisposing risk factors, exertional heat illnesses or symptomatic 335 
clinical populations are expected to be less resistant to cooling due to hypothalamic dysfunction 336 
 
 
and CBT regulation disruption after the traumatic event occurs (6,60–65). Extending the 337 
evaluation of the CAERvest® to other symptomatic populations warrants further investigation. 338 
4.3 Perceptual responses 339 
While perceptual measures are important for investigating cooling interventions (57), most 340 
studies use perceived comfort to assess efficacy prior to and during physical activity in an attempt 341 
to enhance performance (12,66), or reduce physiological strain (57). As expected, TSS decreased 342 
during cooling in all four trials, although no interaction effect occurred. Nor were differences 343 
observed in feeling scale within– or between–trials, suggesting the PoC and P3 CAERvest® did 344 
not make participants feel worse over time, although they felt colder and presented minor 345 
shivering responses. 346 
4.4 Limitations and future directions 347 
Aforementioned, the study used healthy, normothermic individuals as opposed to clinical or 348 
hyperthermic populations, who are known to be more susceptible to external cold stimulus. 349 
Therefore, caution should be used if extending the results of this study to the general population. 350 
An additional limitation includes no control trial, although each cooling period was compared 351 
against prior resting measures within– and between–trials. Directions for future CAERvest® 352 
investigations will include evaluation of product efficacy across a range of exercise–induced 353 
hyperthermic individuals, in addition to comparisons against other cooling modalities and 354 
normothermic post–cardiac arrest populations. 355 
5.0 CONCLUSION 356 
This study observed reductions in core and skin temperature without incidence of cold injury in 357 
the proof of concept and latter CAERvest® prototype design. The latest P3 CAERvest® is a 358 
portable, non–powered, easy–to–use device, which may offer an alternative on–site or pre–359 
hospital strategy for those suffering from HRI or ischemic related events, as a single or combined 360 
approach with other modalities, to induce rapid cooling without the prior preparation required. 361 
However, further research is warranted in controlled laboratory and field–based settings to 362 
continue the evaluation and development of this technology. 363 
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FIGURE TITLES 544 
Figure 1: 545 
Schematic of experimental design. Prototype 3 (P3) was introduced after the proof of concept (PoC), 546 
prototype 1 (P1) and prototype (P2) trials, due to refinements in design following analysis and therefore, 547 
were not part of the randomization. 548 
Note: The full colour version of this figure is available online.  549 
Figure 2: 550 
Schematic of experimental design. 551 
A- Body mass, stature, body surface area, body mass index, hydration status, blood pressure. 552 
B- Physiological (rectal temperature, skin temperature and heart rate) and perceptual (thermal 553 
sensation, cold discomfort, feeling, shivering) measures monitored continuously and recorded 554 
every 5 min. 555 
C- Medical inspection for any associated cold related injuries. 556 
Note: PoC = proof of concept, P1 = prototype 1, P2 = prototype 2 and P3 = prototype 3.  557 
Figure 3.  558 
Photo of prototype 3 on a participant. 559 
Note: The full colour version of this figure is available online.  560 
Figure 4.  561 
Mean rectal temperature changes over the cooling period. Significance (p<0.05) is denoted by ‡ 562 
between PoC and P1, * between P3 and P1.  563 
Note: PoC = proof of concept, P1 = prototype 1, P2 = prototype 2 and P3 = prototype 3.  564 
Figure 5.  565 
Mean skin temperature changes over the cooling period. Significance (p<0.05) is denoted by * between 566 
P3 and P2, and ‡ between P3 and PoC.  567 
Note: PoC = proof of concept, P1 = prototype 1, P2 = prototype 2 and P3 = prototype 3.  568 
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Tables 570 
 571 
Table 1. Mean (SD) preliminary health measures on the arrival to each trial. 
Measure 
Trial 
PoC P1 P2 P3 
NBM (kg) 81.1 ± 15.2 81.2 ± 15.1 76.1 ± 10.2 80.0 ±15.7 
BMI 24.6 ± 4.0 246 ± 3.9 23.1 ± 2.8 24.2 ± 3.9 
BSA (m2) 2.01 ± 0.19 2.01 ± 0.19 1.96 ± 0.14 2.00 ± 0.20 
Systolic BP (mmHg) 148 ± 18* 144 ± 17 135 ± 5 134 ± 10 
Diastolic BP (mmHg) 81 ± 12 79 ± 5 81 ± 6 79 ± 6 
Uosm (mOsmol·kg–1 H2O) 491 ± 104 524 ± 228 450 ± 157 389 ± 213 
Usg 1.013 ± 0.004 1.014 ± 0.008 1.010 ± 0.005 1.010 ± 0.006 
Note: * denotes significant difference between other trials, where p<0.05. PoC = proof of concept, P1 = 
prototype 1, P2 = prototype 2 and P3 = prototype 3. BP = blood pressure, BMI = body mass index, 
BSA = body surface area, NBM = nude body mass, Uosm = urine osmolality, Usg = urine specific 
gravity.  
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Table 2. Mean (SD) and change in baseline physiological and perceptual measures. 
Measure Trial 
PoC P1 P2 P3 
Tre (°C) M 37.11 ± 0.29 37.10 ± 0.26 37.10 ± 0.27 37.18 ± 0.26 
∆ –0.13 ± 0.10 –0.14 ± 0.13 –0.09 ± 0.10 –0.11 ± 0.07 
Tskin (°C) M 31.29 ± 1.01 31.14 ± 1.02 30.92 ± 1.43 30.97 ± 1.18 
∆ 1.08 ± 0.38 1.11 ± 0.76 1.04 ± 0.60 1.04 ± 0.45 
HR (bpm) M 63 ± 8 61 ± 9 64 ± 7 63 ± 9 
∆ –1 ± 6 –2 ± 7 –1 ± 8 –1 ± 4 
TSS M 4 ± 1 4 ± 1 4 ± 0 4 ± 1 
∆ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Shivering M 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
∆ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Feeling M 2 ± 2 3 ± 2 2 ± 2 2 ± 2 
∆ 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Cold 
discomfort 
M 1 ± 1 0 ± 1 0 ± 0 0 ± 1 
∆ 0 ± 0 0 ± 0 0 ± 0 0 ± 1 
Note: PoC = proof of concept, P1 = prototype 1, P2 = prototype 2 and P3 = prototype 3. ∆ = 
change, HR = heart rate, M = mean, Tre = core temperature, Tskin = skin temperature, and TSS = 
thermal sensation scale. 
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Table 3. Pre–post mean (SD) changes in physiological measures during cooling. 
Measure Trial Time (min) 
0 min 60 min ∆ 0–60 
Tre (°C) PoC 37.04 ± 0.29 36.68 ± 0.42 –0.36 ± 0.18*+ 
P1 37.03 ± 0.23 36.86 ± 0.26 –0.17 ± 0.13* 
P2 37.06 ± 0.27 36.87 ± 0.24 –0.19 ± 0.17* 
P3 37.12 ± 0.23 36.76 ± 0.28 –0.36 ± 0.22* 
Tskin (°C) PoC 31.76 ± 1.12 30.18 ± 1.38 –1.55 ± 0.97* 
P1 31.59 ± 0.95 29.39 ± 0.62 –2.20 ± 1.04* 
P2 31.33 ± 1.50 30.35 ± 1.22 –0.98 ± 0.93* 
P3 31.42 ± 1.14 28.95 ± 1.10 –2.47 ± 0.82*† 
HR (bpm) PoC 63 ± 10 56 ± 9 –7 ± 12 
P1 60 ± 8 53 ± 7 –7 ± 3 
P2 65 ± 6 60 ± 6 –5 ± 4 
P3 63 ± 9 56 ± 8 –7 ± 8 
Note: * denotes significant (p<0.05) difference within trials for pre to post changes, + between PoC 
and P1, and † between P3 and P2 change. PoC = proof of concept, P1 = prototype 1, P2 = prototype 
2 and P3 = prototype 3. ∆ = change, Tre = core temperature and Tskin = skin temperature. 
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Table 4. Pre–post mean (SD) changes in perceptual measures during cooling. 
Measure Trial Time (min) 
0 min 60 min ∆ 0–60 
TSS 
 
PoC 4 ± 1 2 ± 1 –2 ± 1* 
P1 4 ± 1 3 ± 1 –1 ± 1* 
P2 4 ± 0 3 ± 1 –1 ± 1* 
P3 4 ± 1 2 ± 1 –2 ± 1* 
 
Shivering 
 
PoC 0 ± 0 1 ± 1 1 ± 1§ 
P1 0 ± 0 0 ± 0 0 ± 0 
P2 0 ± 0 0 ± 0 0 ± 0 
P3 0 ± 0 1 ± 1 1 ± 1 
 
Feeling  
 
PoC 2 ± 2 0 ± 3 –2 ± 2 
P1 3 ± 2 1 ± 3 –1 ± 2 
P2 2 ± 2 1 ± 3 –1 ± 1 
 P3 2 ± 2 0 ± 3 –1 ± 2 
Cold discomfort PoC 1 ± 1 4 ± 2 4 ± 2* 
P1 0 ± 1 3 ± 3 2 ± 3* 
P2 0 ± 0 3 ± 2 3 ± 2* 
P3 1 ± 1 5 ± 2 4 ± 2* 
Note: * denotes significant (p<0.05) difference within trials for pre to post changes, § 
between P1 and P2. PoC = proof of concept, P1 = prototype 1, P2 = prototype 2 and P3 = 
prototype 3. ∆ = change and TSS = thermal sensation scale. 
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